LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

Adaptive Biotechnologies Corp

Aperta

10.51 1.55

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.16

Massimo

10.62

Metriche Chiave

By Trading Economics

Entrata

3.9M

-30M

Vendite

5M

52M

EPS

-0.2

Margine di Profitto

-56.881

Dipendenti

619

EBITDA

-3.3M

-30M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+14.26% upside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

413M

1.6B

Apertura precedente

8.96

Chiusura precedente

10.51

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 giu 2025, 18:52 UTC

Utili

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22 giu 2025, 23:59 UTC

Discorsi di Mercato

Gold Edges Higher Amid Worries Over Middle East Conflict -- Market Talk

22 giu 2025, 23:55 UTC

Discorsi di Mercato

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22 giu 2025, 23:51 UTC

Discorsi di Mercato

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22 giu 2025, 23:43 UTC

Discorsi di Mercato

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22 giu 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22 giu 2025, 23:11 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 giu 2025, 23:11 UTC

Discorsi di Mercato

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22 giu 2025, 22:59 UTC

Discorsi di Mercato

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22 giu 2025, 21:43 UTC

Discorsi di Mercato

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21 giu 2025, 08:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

21 giu 2025, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

21 giu 2025, 08:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

20 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 giu 2025, 20:13 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 giu 2025, 20:11 UTC

Discorsi di Mercato

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 giu 2025, 19:56 UTC

Discorsi di Mercato

Crude Oil Slips to End Week -- Market Talk

20 giu 2025, 18:35 UTC

Discorsi di Mercato

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 giu 2025, 18:12 UTC

Discorsi di Mercato

Gold Slides to Close Shortened Week -- Market Talk

20 giu 2025, 17:56 UTC

Discorsi di Mercato

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 giu 2025, 17:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 giu 2025, 17:35 UTC

Acquisizioni, Fusioni, Takeovers

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 giu 2025, 17:30 UTC

Discorsi di Mercato
Utili

Adobe's AI Headwinds Seen Fading -- Market Talk

20 giu 2025, 17:03 UTC

Utili

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 giu 2025, 16:50 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

20 giu 2025, 16:50 UTC

Discorsi di Mercato
Utili

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 giu 2025, 16:44 UTC

Acquisizioni, Fusioni, Takeovers

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 giu 2025, 16:40 UTC

Discorsi di Mercato
Utili

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Confronto tra pari

Modifica del prezzo

Adaptive Biotechnologies Corp Previsione

Obiettivo di Prezzo

By TipRanks

14.26% in crescita

Previsioni per 12 mesi

Media 11.86 USD  14.26%

Alto 15 USD

Basso 9 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Adaptive Biotechnologies Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.81 / 10.18Supporto e resistenza

A breve termine

Very Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.